Synpromics announces £5.2M British investment in gene therapy tech – BioPharma-Reporter.com
BioPharma-Reporter.com |
Synpromics announces £5.2M British investment in gene therapy tech
BioPharma-Reporter.com The promoters allow for precise control of gene function, impacting gene therapy, cell therapy and gene editing. Synpromics CEO David Venables described the distinct nature of the PromPT platform late last year as a “unique capability for the … Synpromics Raises £5.2M of New Investment Biotech firm Synpromics secures £5.2m cash injection |
